Orlistat

Nina N. Wong, Angela Cheng-Lai

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Obesity is a risk factor for cardiovascular disease. Orlistat is a gastric and pancreatic lipase inhibitor indicated for the management of obesity. It is the first antiobesity agent that is not a centrally acting appetite suppressant; instead, it decreases absorption of dietary fat in the gastrointestinal tract. The effects of orlistat on weight loss, weight regain, and on a number of obesity-related risk factors have been assessed in large clinical trials of 1 to 2 years' duration. Compared with subjects who received placebo and a hypocaloric diet alone, weight loss of at least 5 to 10% of initial body weight was observed in a significantly larger number of subjects who were treated with orlistat plus a hypocaloric diet during the first year of treatment. Subjects who received orlistat 120 mg three times daily regained significantly less weight than subjects who received placebo during the second year of treatment. In addition, orlistat was found to have favorable effects on blood pressure and concentrations of serum lipid, glucose, and insulin. Gastrointestinal events are the most common adverse effects experienced by patients who received orlistat; however, most of these events were mild to moderate in intensity, transient in duration, and decreased considerably during the second year of treatment.

Original languageEnglish (US)
Pages (from-to)174-181
Number of pages8
JournalHeart Disease
Volume2
Issue number2
StatePublished - Mar 2000

Fingerprint

Obesity
Placebos
Anti-Obesity Agents
Reducing Diet
Weights and Measures
Appetite Depressants
Dietary Fats
Lipase
Gastrointestinal Tract
orlistat
Weight Loss
Stomach
Cardiovascular Diseases
Therapeutics
Body Weight
Clinical Trials
Insulin
Diet
Blood Pressure
Lipids

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Wong, N. N., & Cheng-Lai, A. (2000). Orlistat. Heart Disease, 2(2), 174-181.

Orlistat. / Wong, Nina N.; Cheng-Lai, Angela.

In: Heart Disease, Vol. 2, No. 2, 03.2000, p. 174-181.

Research output: Contribution to journalArticle

Wong, NN & Cheng-Lai, A 2000, 'Orlistat', Heart Disease, vol. 2, no. 2, pp. 174-181.
Wong NN, Cheng-Lai A. Orlistat. Heart Disease. 2000 Mar;2(2):174-181.
Wong, Nina N. ; Cheng-Lai, Angela. / Orlistat. In: Heart Disease. 2000 ; Vol. 2, No. 2. pp. 174-181.
@article{afb8e63341fd4159963b5cd1e8d283cc,
title = "Orlistat",
abstract = "Obesity is a risk factor for cardiovascular disease. Orlistat is a gastric and pancreatic lipase inhibitor indicated for the management of obesity. It is the first antiobesity agent that is not a centrally acting appetite suppressant; instead, it decreases absorption of dietary fat in the gastrointestinal tract. The effects of orlistat on weight loss, weight regain, and on a number of obesity-related risk factors have been assessed in large clinical trials of 1 to 2 years' duration. Compared with subjects who received placebo and a hypocaloric diet alone, weight loss of at least 5 to 10{\%} of initial body weight was observed in a significantly larger number of subjects who were treated with orlistat plus a hypocaloric diet during the first year of treatment. Subjects who received orlistat 120 mg three times daily regained significantly less weight than subjects who received placebo during the second year of treatment. In addition, orlistat was found to have favorable effects on blood pressure and concentrations of serum lipid, glucose, and insulin. Gastrointestinal events are the most common adverse effects experienced by patients who received orlistat; however, most of these events were mild to moderate in intensity, transient in duration, and decreased considerably during the second year of treatment.",
author = "Wong, {Nina N.} and Angela Cheng-Lai",
year = "2000",
month = "3",
language = "English (US)",
volume = "2",
pages = "174--181",
journal = "Heart Disease",
issn = "1521-737X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Orlistat

AU - Wong, Nina N.

AU - Cheng-Lai, Angela

PY - 2000/3

Y1 - 2000/3

N2 - Obesity is a risk factor for cardiovascular disease. Orlistat is a gastric and pancreatic lipase inhibitor indicated for the management of obesity. It is the first antiobesity agent that is not a centrally acting appetite suppressant; instead, it decreases absorption of dietary fat in the gastrointestinal tract. The effects of orlistat on weight loss, weight regain, and on a number of obesity-related risk factors have been assessed in large clinical trials of 1 to 2 years' duration. Compared with subjects who received placebo and a hypocaloric diet alone, weight loss of at least 5 to 10% of initial body weight was observed in a significantly larger number of subjects who were treated with orlistat plus a hypocaloric diet during the first year of treatment. Subjects who received orlistat 120 mg three times daily regained significantly less weight than subjects who received placebo during the second year of treatment. In addition, orlistat was found to have favorable effects on blood pressure and concentrations of serum lipid, glucose, and insulin. Gastrointestinal events are the most common adverse effects experienced by patients who received orlistat; however, most of these events were mild to moderate in intensity, transient in duration, and decreased considerably during the second year of treatment.

AB - Obesity is a risk factor for cardiovascular disease. Orlistat is a gastric and pancreatic lipase inhibitor indicated for the management of obesity. It is the first antiobesity agent that is not a centrally acting appetite suppressant; instead, it decreases absorption of dietary fat in the gastrointestinal tract. The effects of orlistat on weight loss, weight regain, and on a number of obesity-related risk factors have been assessed in large clinical trials of 1 to 2 years' duration. Compared with subjects who received placebo and a hypocaloric diet alone, weight loss of at least 5 to 10% of initial body weight was observed in a significantly larger number of subjects who were treated with orlistat plus a hypocaloric diet during the first year of treatment. Subjects who received orlistat 120 mg three times daily regained significantly less weight than subjects who received placebo during the second year of treatment. In addition, orlistat was found to have favorable effects on blood pressure and concentrations of serum lipid, glucose, and insulin. Gastrointestinal events are the most common adverse effects experienced by patients who received orlistat; however, most of these events were mild to moderate in intensity, transient in duration, and decreased considerably during the second year of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0034158511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034158511&partnerID=8YFLogxK

M3 - Article

C2 - 11728255

AN - SCOPUS:0034158511

VL - 2

SP - 174

EP - 181

JO - Heart Disease

JF - Heart Disease

SN - 1521-737X

IS - 2

ER -